SUMMARY The efficacy and tolerability of oxcarbazepine, a keto derivative of carbamazepine, has been assessed in six patients (two males, four females; mean age 61 years, range 42-77), with trigeminal neuralgia refractory to carbamazepine therapy, over a period of 6 months. An excellent therapeutic response to oxcarbazepine was seen in all patients with pain control correlating well with serum drug concentrations of oxcarbazepine and its primary active metabolite 10-OH-carbazepine. Onset of the effect was observed within 24 hours in all cases. An overall serum therapeutic concentration range, in the six patients, of 50-110 imol/l of 10-OH-carbazepine corresponding to a daily effective dose range of 1200-2400 mg (14 6-35-6 mg/kg body weight) oxcarbazepine, was observed. There was a significant correlation between oxcarbazepine dose and serum oxcarbazepine (r = 0 695, p < 0-05) and 10-OH-carbazepine (r = 0 957, p < 0-001) concentrations. Oxcarbazepine was well tolerated and no significant side effects were identified, though a mild hyponatraemia was observed during high doses (>28 and >35 mg/kg/day) in two patients. It is concluded that oxcarbazepine has potent antineuralgic properties in the absence of significant side effects and therefore may be useful in the management of intractable trigeminal neuralgia.
Carbamazepine is currently the drug of choice in the management of trigeminal neuralgia with an onset of action within 24 hours.' It is efficacious in only 70-80% of patients, and can be associated with toxicity manifested by drowsiness, confusion, nausea, ataxia, nystagmus and hypersensitivity necessitating discontinuation of medication.56 Twenty per cent of patients responding initially to treatment may subsequently become refractory to carbamazepine. 7 Oxcarbazepine (10,1 1-dihydro-10-oxo-5H-dibenz-(b,f)azepine-5-carboxamide), a keto derivative of carbamazepine, has been shown to have equal efficacy to carbamazepine in the management of epilepsy but with less side effects and greater tolerance."' Oxcarbazepine is rapidly absorbed after oral ingestion" 2 and is metabolised to two major metabolites, 10,1 1-dihydro-I0-hydroxycarbamazepine (10-OH-carbazepine) and trans-10, 1 1-dihydro-10, 11 -dihydroxy-carbamazepine. 10-OH-carbazepine is the primary metabolite and is active pharmacologically as an anticonvulsant drug.'3 Additionally, oxcarbazepine has been found useful in the management of affective disorders'4 and spasticity. '5 Recently, Farago (1987) 6 in a series of 13 patients with trigeminal neuralgia has reported that oxcarbazepine has antineuralgic properties in the absence of significant side effects.
The present evaluation was designed to assess the efficacy and tolerability of oxcarbazepine in the management of trigeminal neuralgia in 6 patients refractory to carbamazepine therapy over a period of 6 months and to determine systematically individual therapeutic doses of oxcarbazepine and therapeutic serum concentration ranges for 10-OH-carbazepine, the primary active metabolite of oxcarbazepine.
Patients and methods
All six patients had classical idiopathic trigeminal neuralgia as indicated by the following criteria: (1) pain in the distribution of the trigeminal nerve; (2) pain of "electric shock", shooting or stabbing character of short duration; (3) pain provoked by innocuous stimuli such as light touch or vibration; (4) paroxysmal pain with episodes of complete 472 remission; (5) 
Results
Oxcarbazepine dosage ranged from 600 mg to 2400 mg/day. Steady state serum oxcarbazepine and 10-OH-carbazepine concentrations at 3-4 hours after the morning dose ranged from 0-0-11 4 Zakrzewska, Patsalos patients during 6 months of oxcarbazepine therapy is shown in figs 1 and 2. For clarity and because serum oxcarbazepine was not detectable at the lower oxcarbazepine doses, serum oxcarbazepine concentrations have been omitted from the figures. The daily pain scores shown (maximum score = 24) are those of the 24 hour period prior to the morning serum 10-OHcarbazepine concentration. There was a wide interindividual range both prior to oxcarbazepine treatment (day 0) and during the six month assessment period and this is a reflection to some extent, of the clinical condition with spontaneous fluctuations in the severity ofthe pain. Additional variation can probably be attributed to inter-individual differences in pain estimation, consequently each patient acted as his/her own control. Pain scores of -7 and above were associated with a decline in ability to eat and talk. The response to oxcarbazepine treatment was dramatic in all patients with the onset of effect occurring in all cases within 24 hours. This is particularly well illustrated by patient 2 (fig 2) who had been unable to maintain good oral hygiene prior to commencement of oxcarbazepine therapy (fig 3) . 10-OH-carbazepine concentration ranges were determined for each patient and these data are shown in table 2. Pain control correlated well with serum 10-OH-carbazepine concentration with excellent overall pain alleviation in our 6 patients when serum 10-OHcarbazepine concentrations were in the range 50-110 pmol/l. Large changes in serum 10-OH-carbazepine concenrations were associated with pronounced and almost immediate alteration in pain score (for example fig 2, day 49 ). Anxiety and depression scores in three of the four patients assessed were reduced by an average of 43% and 59% respectively. The continuing depression seen in the fourth patient can be attributed to a cardiac condition and his anaesthesia dolorosa.
No clinical side effects were observed although a mild hyponatraemia (Na = 123-131 mmol/l) was seen in two patients taking high doses (> 28 mg/kg/d and >35 mg/kg/d) of oxcarbazepine. One of these patients had an associated 1 kg weight gain. All other haematological and biochemical parameters were normal.
Discussion
Oxcarbazepine has been used to treat systematically six patients with intractable trigeminal neuralgia over a period of 6 months and good therapeutic responses have been observed. The associated reduction in the anxiety and depression score in three of the four patients tested, reflected the very clear improvement in the patients' quality of life.
Since oxcarbazepine is rapidly metabolised to 10-OH-carbazepine it is difficult to ascertain which A placebo effect in trigeminal neuralgia is negligible,3 therefore the significant correlation between serum oxcarbazepine and 10-OH-carbazepine concentrations and pain control suggests that the measurement of either would be a good index of therapeutic efficacy. However, the fact that serum 10-OH-carbazepine concentrations are 15-30 fold higher than that of oxcarbazepine, and that pharmacologically 10-OH-carbazepine may be more important, indicates that the measurement of serum 10-OHcarbazepine is perhaps more appropriate.
The optimal serum therapeutic range, in our patients, for 10-OH-carbazepine was 50-110 imol/l and compares well with that previously reported (35-100 gmol/1).'6 No adverse side effects were reported by our patients and the allergic skin reaction, present in two patients which were hypersensitive to carbamazepine, completely cleared during oxcarbazepine therapy. The hyponatraemia that has been associated with oxcarbazepine therapy2021 was only observed at the high doses (>28 and >35 mg/kg/day in two different patients), was mild and essentially clinically asymptomatic. It is concluded from the present study that oxcarbazepine has potent antineuralgic properties in the absence of significant side effects and therefore may be useful in the management of intractable trigeminal neuralgia. 
